SG11201602269QA - Hydrochloride salt form for ezh2 inhibition - Google Patents
Hydrochloride salt form for ezh2 inhibitionInfo
- Publication number
- SG11201602269QA SG11201602269QA SG11201602269QA SG11201602269QA SG11201602269QA SG 11201602269Q A SG11201602269Q A SG 11201602269QA SG 11201602269Q A SG11201602269Q A SG 11201602269QA SG 11201602269Q A SG11201602269Q A SG 11201602269QA SG 11201602269Q A SG11201602269Q A SG 11201602269QA
- Authority
- SG
- Singapore
- Prior art keywords
- salt form
- hydrochloride salt
- ezh2 inhibition
- ezh2
- inhibition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361891786P | 2013-10-16 | 2013-10-16 | |
PCT/US2014/060724 WO2015057859A1 (fr) | 2013-10-16 | 2014-10-15 | Forme saline d'hydrochlorure pour inhibition d'ezh2 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201602269QA true SG11201602269QA (en) | 2016-04-28 |
Family
ID=52828660
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201602269QA SG11201602269QA (en) | 2013-10-16 | 2014-10-15 | Hydrochloride salt form for ezh2 inhibition |
SG10201901977XA SG10201901977XA (en) | 2013-10-16 | 2014-10-15 | Hydrochloride salt form for ezh2 inhibition |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201901977XA SG10201901977XA (en) | 2013-10-16 | 2014-10-15 | Hydrochloride salt form for ezh2 inhibition |
Country Status (24)
Country | Link |
---|---|
US (3) | US10040782B2 (fr) |
EP (2) | EP4324525A3 (fr) |
JP (2) | JP6608812B2 (fr) |
KR (1) | KR102142177B1 (fr) |
CN (1) | CN105829302B (fr) |
AU (2) | AU2014337300B2 (fr) |
CA (1) | CA2925889C (fr) |
CL (1) | CL2016000866A1 (fr) |
DK (1) | DK3057962T3 (fr) |
EA (1) | EA038869B1 (fr) |
ES (1) | ES2960953T3 (fr) |
FI (1) | FI3057962T3 (fr) |
HU (1) | HUE063984T2 (fr) |
IL (1) | IL244787B (fr) |
LT (1) | LT3057962T (fr) |
MA (1) | MA38949A1 (fr) |
MX (1) | MX2016004703A (fr) |
MY (1) | MY179802A (fr) |
PE (1) | PE20161273A1 (fr) |
PL (1) | PL3057962T3 (fr) |
PT (1) | PT3057962T (fr) |
SG (2) | SG11201602269QA (fr) |
SI (1) | SI3057962T1 (fr) |
WO (1) | WO2015057859A1 (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112014025508B1 (pt) | 2012-04-13 | 2020-11-17 | Eisai R&D Management Co., Ltd. | forma de sal de um inibidor de histona metiltransferase ezh2 humana |
EP4324525A3 (fr) | 2013-10-16 | 2024-07-17 | Epizyme, Inc. | Forme saline d'hydrochlorure pour inhibition d'ezh2 |
IL282741B2 (en) | 2013-12-06 | 2024-01-01 | Epizyme Inc | Tazematostat in combination with an acceptable treatment factor for use in the treatment of cancer |
MX2021007651A (es) | 2014-06-17 | 2021-08-11 | Epizyme Inc | Inhibidores de ezh2 para tratar linfomas. |
CA2963149A1 (fr) | 2014-10-16 | 2016-04-21 | Epizyme, Inc. | Methode de traitement du cancer |
AU2015350108B2 (en) | 2014-11-17 | 2021-04-08 | Eisai R&D Management Co., Ltd. | Method for treating cancer |
EA201792304A1 (ru) | 2015-04-20 | 2018-03-30 | Эпизайм, Инк. | Комбинированная терапия для лечения рака |
CN107635965A (zh) | 2015-06-10 | 2018-01-26 | Epizyme股份有限公司 | 用于治疗淋巴瘤的ezh2抑制剂 |
US10493076B2 (en) | 2015-08-24 | 2019-12-03 | Epizyme, Inc. | Method for treating cancer |
AU2017211331A1 (en) | 2016-01-29 | 2018-06-07 | Epizyme, Inc. | Combination therapy for treating cancer |
WO2017210395A1 (fr) | 2016-06-01 | 2017-12-07 | Epizyme, Inc. | Utilisation d'inhibiteurs de ezh2 pour le traitement du cancer |
WO2017218953A1 (fr) | 2016-06-17 | 2017-12-21 | Epizyme, Inc. | Inhibiteurs d'ezh2 pour traiter le cancer |
US11311524B2 (en) | 2017-01-19 | 2022-04-26 | Daiichi Sankyo Company, Limited | Pharmaceutical composition used for treatment of HTLV-1-associated myelopathy |
WO2018183885A1 (fr) | 2017-03-31 | 2018-10-04 | Epizyme, Inc. | Multithérapie pour le traitement du cancer |
JP2020522687A (ja) | 2017-06-02 | 2020-07-30 | エピザイム,インコーポレイティド | 癌を処置するためのezh2阻害剤の使用 |
JP7399079B2 (ja) | 2017-09-05 | 2023-12-15 | エピザイム,インコーポレイティド | 癌を処置するための併用療法 |
CN112399857A (zh) | 2018-07-09 | 2021-02-23 | 盲人庇护基金会 | Prc2亚单位的抑制治疗眼失调 |
KR20220066892A (ko) | 2019-08-22 | 2022-05-24 | 주노 쎄러퓨티크스 인코퍼레이티드 | T 세포 요법 및 제스트 동족체 2의 인핸서 (ezh2) 억제제의 병용 요법 및 관련 방법 |
WO2023209591A1 (fr) | 2022-04-27 | 2023-11-02 | Daiichi Sankyo Company, Limited | Combinaison d'un conjugué anticorps-médicament avec un inhibiteur de l'ezh1 et/ou de l'ezh2 |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0733729A (ja) | 1993-07-26 | 1995-02-03 | Kirin Brewery Co Ltd | N−シアノ−n′−置換−アリールカルボキシイミダミド化合物の製造法 |
KR100189863B1 (ko) | 1993-12-27 | 1999-06-01 | 나이또 하루오 | 안트라닐산 유도체 |
DE19516776A1 (de) | 1995-05-10 | 1996-11-14 | Boehringer Ingelheim Int | Chromatin-Regulatorgene |
US5741819A (en) | 1995-06-07 | 1998-04-21 | 3-Dimensional Pharmaceuticals, Inc. | Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors |
JP3906935B2 (ja) | 1995-12-18 | 2007-04-18 | 杏林製薬株式会社 | N−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
BR9914207A (pt) | 1998-09-30 | 2001-07-03 | Procter & Gamble | Ceto-amidas 2-substituìdas |
UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
US6710058B2 (en) | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
PT1357111E (pt) | 2000-12-28 | 2009-10-20 | Shionogi & Co | Derivados de 2-piridona com afinidade para receptores de canabinóides do tipo 2 |
US7700293B2 (en) | 2001-08-02 | 2010-04-20 | The Regents Of The University Of Michigan | Expression profile of prostate cancer |
DE60329981D1 (de) | 2002-02-19 | 2009-12-24 | Shionogi & Co | Antipruriginosa |
TW200306155A (en) | 2002-03-19 | 2003-11-16 | Du Pont | Benzamides and advantageous compositions thereof for use as fungicides |
US7442685B2 (en) | 2003-06-13 | 2008-10-28 | The University Of North Carolina At Chapel Hill | DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia |
WO2005118796A2 (fr) | 2004-06-01 | 2005-12-15 | The University Of North Carolina At Chapel Hill | Complexe d'histone methyltransferase reconstitue et methodes associees d'identification de modulateurs |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
DE602006019423D1 (de) | 2005-06-02 | 2011-02-17 | Univ North Carolina | Reinigung, charakterisierung und wiederherstellung einer ubiquitin-e3-ligase |
FR2889526B1 (fr) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
EP1940821B1 (fr) | 2005-10-19 | 2013-03-20 | Grünenthal GmbH | Nouveaux ligands du recepteur vanilloide et leur utilisation dans la production de medicaments |
JP4931930B2 (ja) | 2005-10-21 | 2012-05-16 | メルク・シャープ・エンド・ドーム・コーポレイション | カリウムチャネル阻害剤 |
AU2006308957B2 (en) | 2005-10-28 | 2012-04-12 | The University Of North Carolina At Chapel Hill | Protein demethylases comprising a JmjC domain |
JP2009519966A (ja) | 2005-12-14 | 2009-05-21 | ブリストル−マイヤーズ スクイブ カンパニー | セリンプロテアーゼ阻害剤として有用な6員ヘテロ環 |
EP1974055A4 (fr) | 2006-01-20 | 2010-01-27 | Univ North Carolina | Cibles diagnostiques et therapeutiques pour la leucemie |
RU2008149246A (ru) | 2006-05-15 | 2010-06-20 | Айрм Ллк (Bm) | Соединение на основе терефталата, композиции и их применение в качестве ингибиторов интегразы вич |
CA2652634A1 (fr) | 2006-05-18 | 2007-11-29 | Amphora Discovery Corporation | Certaines quinolones substituees, compositions et utilisations |
EP2086318A4 (fr) | 2006-10-10 | 2009-12-23 | Burnham Inst Medical Research | Compositions neuroprotectrices et procédés correspondants |
JP2010519204A (ja) | 2007-02-16 | 2010-06-03 | アムジエン・インコーポレーテツド | 窒素含有複素環ケトン類およびそれらのc−Met阻害薬としての使用 |
US8338437B2 (en) | 2007-02-28 | 2012-12-25 | Methylgene Inc. | Amines as small molecule inhibitors |
WO2008113006A1 (fr) | 2007-03-14 | 2008-09-18 | Xenon Pharmaceuticals Inc. | Procédés d'utilisation de composés à base de quinolinone dans le traitement des maladies ou des affections associées aux canaux sodiques |
DE102007017884A1 (de) | 2007-04-13 | 2008-10-16 | Grünethal GmbH | Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln |
US20090012031A1 (en) | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | EZH2 Cancer Markers |
JP2011502148A (ja) | 2007-10-31 | 2011-01-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 疼痛の治療用としてのp2x3受容体アンタゴニスト |
EP2229391B1 (fr) | 2007-12-19 | 2014-08-06 | Cancer Research Technology Limited | Composés pyrido[2,3-b]pyrazine substitués en position 8 et leur utilisation |
WO2009124137A2 (fr) | 2008-04-01 | 2009-10-08 | Mount Sinai School Of Medicine Of New York University | Procédé de suppression d’une transcription de gène par méthylation d’histone lysine |
US20100113415A1 (en) | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
WO2010017355A2 (fr) | 2008-08-08 | 2010-02-11 | New York Blood Center | Inhibiteurs à petite molécule d’assemblage et de maturation rétroviraux |
FR2934995B1 (fr) | 2008-08-14 | 2010-08-27 | Sanofi Aventis | Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique |
US20120065247A1 (en) | 2009-03-27 | 2012-03-15 | Discoverybiomed, Inc. | Modulating ires-mediated translation |
WO2011011366A2 (fr) | 2009-07-20 | 2011-01-27 | Constellation Pharmaceuticals | Agents pour stimuler l'activité d'enzymes de modification par méthyle et procédés d'utilisation de ceux-ci |
US8329149B2 (en) | 2009-12-30 | 2012-12-11 | Avon Products, Inc. | Topical lightening composition and uses thereof |
US8846935B2 (en) | 2010-05-07 | 2014-09-30 | Glaxosmithkline Llc | Indazoles |
ME02757B (fr) | 2010-05-07 | 2018-01-20 | Glaxosmithkline Llc | Indoles |
EP2566479B1 (fr) | 2010-05-07 | 2014-12-24 | GlaxoSmithKline LLC | Aza-indazoles |
EP2614369B1 (fr) | 2010-09-10 | 2016-02-03 | Epizyme, Inc. | Procédé de détermination de l'utilité d'inhibiteurs de l'ezh2 humaine |
US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
US20130310379A1 (en) | 2010-11-19 | 2013-11-21 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
WO2012075080A1 (fr) | 2010-12-01 | 2012-06-07 | Glaxosmithkline Llc | Indoles |
CN103339139A (zh) | 2010-12-03 | 2013-10-02 | Epizyme股份有限公司 | 组蛋白甲基转移酶的7-氮杂嘌呤调节剂及其使用方法 |
EP3323820B1 (fr) | 2011-02-28 | 2023-05-10 | Epizyme, Inc. | Composés hétéroaryles bicycliques substitués condensés en 6,5 |
JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
EP3536314A1 (fr) | 2012-03-12 | 2019-09-11 | Epizyme, Inc. | Inhibiteurs de ezh2 humain et procédés d'utilisation associés |
BR112014025508B1 (pt) | 2012-04-13 | 2020-11-17 | Eisai R&D Management Co., Ltd. | forma de sal de um inibidor de histona metiltransferase ezh2 humana |
IL289300B2 (en) | 2012-04-13 | 2024-05-01 | Epizyme Inc | Combined treatment for cancer |
WO2013173441A2 (fr) | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Inhibiteurs d'homologue d'activateur de zeste 2 |
MY180311A (en) | 2012-10-15 | 2020-11-28 | Epizyme Inc | Substituted benzene compounds |
HUE046790T2 (hu) | 2012-10-15 | 2020-03-30 | Epizyme Inc | A rák kezelésének módszerei |
EP2935264B1 (fr) | 2012-12-21 | 2017-10-18 | Epizyme, Inc. | Composés hétéroaryles bicycliques 1,4-pyridone |
CA2894216A1 (fr) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Composes 1,4-pyridones |
EP2970306A4 (fr) | 2013-03-15 | 2016-08-03 | Epizyme Inc | Composés hétéroaryles bicycliques substitués condensés en 6,5 |
WO2014172044A1 (fr) | 2013-03-15 | 2014-10-23 | Epizyme, Inc. | Composés de benzène substitués |
US10150764B2 (en) | 2013-07-19 | 2018-12-11 | Epizyme, Inc. | Substituted benzene compounds |
EP3022195A2 (fr) | 2013-07-19 | 2016-05-25 | Epizyme, Inc. | Composés hétéroaryles bicycliques substitués condensés en 6,5 |
EP4324525A3 (fr) | 2013-10-16 | 2024-07-17 | Epizyme, Inc. | Forme saline d'hydrochlorure pour inhibition d'ezh2 |
-
2014
- 2014-10-15 EP EP23203529.5A patent/EP4324525A3/fr active Pending
- 2014-10-15 PT PT148542723T patent/PT3057962T/pt unknown
- 2014-10-15 LT LTEPPCT/US2014/060724T patent/LT3057962T/lt unknown
- 2014-10-15 MY MYPI2016000542A patent/MY179802A/en unknown
- 2014-10-15 CA CA2925889A patent/CA2925889C/fr active Active
- 2014-10-15 MA MA38949A patent/MA38949A1/fr unknown
- 2014-10-15 SI SI201432051T patent/SI3057962T1/sl unknown
- 2014-10-15 KR KR1020167011534A patent/KR102142177B1/ko active IP Right Grant
- 2014-10-15 HU HUE14854272A patent/HUE063984T2/hu unknown
- 2014-10-15 FI FIEP14854272.3T patent/FI3057962T3/fi active
- 2014-10-15 AU AU2014337300A patent/AU2014337300B2/en active Active
- 2014-10-15 EA EA201690650A patent/EA038869B1/ru unknown
- 2014-10-15 SG SG11201602269QA patent/SG11201602269QA/en unknown
- 2014-10-15 SG SG10201901977XA patent/SG10201901977XA/en unknown
- 2014-10-15 PL PL14854272.3T patent/PL3057962T3/pl unknown
- 2014-10-15 ES ES14854272T patent/ES2960953T3/es active Active
- 2014-10-15 WO PCT/US2014/060724 patent/WO2015057859A1/fr active Application Filing
- 2014-10-15 MX MX2016004703A patent/MX2016004703A/es active IP Right Grant
- 2014-10-15 PE PE2016000506A patent/PE20161273A1/es unknown
- 2014-10-15 US US15/029,848 patent/US10040782B2/en active Active
- 2014-10-15 CN CN201480056428.6A patent/CN105829302B/zh active Active
- 2014-10-15 DK DK14854272.3T patent/DK3057962T3/da active
- 2014-10-15 JP JP2016519378A patent/JP6608812B2/ja active Active
- 2014-10-15 EP EP14854272.3A patent/EP3057962B1/fr active Active
-
2016
- 2016-03-28 IL IL244787A patent/IL244787B/en unknown
- 2016-04-13 CL CL2016000866A patent/CL2016000866A1/es unknown
-
2018
- 2018-06-05 US US16/000,539 patent/US10710987B2/en active Active
- 2018-12-11 JP JP2018231817A patent/JP2019052181A/ja active Pending
-
2019
- 2019-04-02 AU AU2019202246A patent/AU2019202246A1/en not_active Abandoned
-
2020
- 2020-06-03 US US16/891,427 patent/US20210017163A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL244787A0 (en) | Hydrochloride salt form for ezh2 inhibition | |
PT3628670T (pt) | Forma salina de um inibidor de ezh2 | |
HK1224298A1 (zh) | 晶體溴結構域抑制劑 | |
HK1220459A1 (zh) | 激酶抑制劑 | |
HK1214813A1 (zh) | 激酶抑制劑 | |
HK1222387A1 (zh) | 作為 抑制劑的芳基吡咯並吡啶衍生的化合物 | |
HK1211578A1 (en) | Amidoimidazopyridazines as mknk-1 kinase inhibitors mknk-1 | |
HK1219104A1 (zh) | 激酶抑制劑 | |
HK1216531A1 (zh) | 新的抑制劑 | |
EP3007689A4 (fr) | Inhibiteurs de kinase non sélectifs | |
EP2968358A4 (fr) | Nouveaux inhibiteurs de choline kinase | |
ZA201506296B (en) | 2-acylaminothiazole derivative or salt thereof | |
HK1232227A1 (zh) | 作為 抑制劑的喹嗪酮衍生物 | |
IL245737B (en) | Glucosylceramide synthase inhibitors | |
PT2900066T (pt) | Método e sistema para o aumento da eficácia biocida de sais de monoalquilditiodiocarbamatos | |
GB201307155D0 (en) | Kinase inhibitors |